154 related articles for article (PubMed ID: 22662244)
1. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.
Pilarski R; Patel DA; Weitzel J; McVeigh T; Dorairaj JJ; Heneghan HM; Miller N; Weidhaas JB; Kerin MJ; McKenna M; Wu X; Hildebrandt M; Zelterman D; Sand S; Shulman LP
PLoS One; 2012; 7(5):e37891. PubMed ID: 22662244
[TBL] [Abstract][Full Text] [Related]
2. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E; Lu L; Boeke M; Barnett R; Nallur S; Chin LJ; Pelletier C; Blitzblau R; Tassi R; Paranjape T; Hui P; Godwin AK; Yu H; Risch H; Rutherford T; Schwartz P; Santin A; Matloff E; Zelterman D; Slack FJ; Weidhaas JB
Cancer Res; 2010 Aug; 70(16):6509-15. PubMed ID: 20647319
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
[TBL] [Abstract][Full Text] [Related]
4. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
8. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929
[TBL] [Abstract][Full Text] [Related]
9. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
10. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
Lorenzo Bermejo J; Hemminki K
Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
[TBL] [Abstract][Full Text] [Related]
12. Contributions of ATM mutations to familial breast and ovarian cancer.
Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ
Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666
[TBL] [Abstract][Full Text] [Related]
13. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
14. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
15. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
Alemar B; Herzog J; Brinckmann Oliveira Netto C; Artigalás O; Schwartz IVD; Matzenbacher Bittar C; Ashton-Prolla P; Weitzel JN
Cancer Genet; 2016 Sep; 209(9):417-422. PubMed ID: 27425403
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and prognostic factors in patients with double primary cancer: epithelial ovarian cancer and breast cancer.
Cvelbar M; Ursic-Vrscaj M; Rakar S
Eur J Gynaecol Oncol; 2005; 26(1):59-63. PubMed ID: 15755003
[TBL] [Abstract][Full Text] [Related]
18. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
Couch FJ; DeShano ML; Blackwood MA; Calzone K; Stopfer J; Campeau L; Ganguly A; Rebbeck T; Weber BL
N Engl J Med; 1997 May; 336(20):1409-15. PubMed ID: 9145677
[TBL] [Abstract][Full Text] [Related]
20. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
; Hollestelle A; van der Baan FH; Berchuck A; Johnatty SE; Aben KK; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Apicella C; Arndt V; Arnold N; Arun BK; Arver B; Ashworth A; ; Baglietto L; Balleine R; Bandera EV; Barrowdale D; Bean YT; Beckmann L; Beckmann MW; Benitez J; Berger A; Berger R; Beuselinck B; Bisogna M; Bjorge L; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bolla MK; Bonanni B; Brand JS; Brauch H; ; Brenner H; Brinton L; Brooks-Wilson A; Bruinsma F; Brunet J; Brüning T; Budzilowska A; Bunker CH; Burwinkel B; Butzow R; Buys SS; Caligo MA; Campbell I; Carter J; Chang-Claude J; Chanock SJ; Claes KBM; Collée JM; Cook LS; Couch FJ; Cox A; Cramer D; Cross SS; Cunningham JM; Cybulski C; Czene K; Damiola F; Dansonka-Mieszkowska A; Darabi H; de la Hoya M; deFazio A; Dennis J; Devilee P; Dicks EM; Diez O; Doherty JA; Domchek SM; Dorfling CM; Dörk T; Silva IDS; du Bois A; Dumont M; Dunning AM; Duran M; Easton DF; Eccles D; Edwards RP; Ehrencrona H; Ejlertsen B; Ekici AB; Ellis SD; ; Engel C; Eriksson M; Fasching PA; Feliubadalo L; Figueroa J; Flesch-Janys D; Fletcher O; Fontaine A; Fortuzzi S; Fostira F; Fridley BL; Friebel T; Friedman E; Friel G; Frost D; Garber J; García-Closas M; Gayther SA; ; ; Gentry-Maharaj A; Gerdes AM; Giles GG; Glasspool R; Glendon G; Godwin AK; Goodman MT; Gore M; Greene MH; Grip M; Gronwald J; Gschwantler Kaulich D; Guénel P; Guzman SR; Haeberle L; Haiman CA; Hall P; Halverson SL; Hamann U; Hansen TVO; Harter P; Hartikainen JM; Healey S; ; Hein A; Heitz F; Henderson BE; Herzog J; T Hildebrandt MA; Høgdall CK; Høgdall E; Hogervorst FBL; Hopper JL; Humphreys K; Huzarski T; Imyanitov EN; Isaacs C; Jakubowska A; Janavicius R; Jaworska K; Jensen A; Jensen UB; Johnson N; Jukkola-Vuorinen A; Kabisch M; Karlan BY; Kataja V; Kauff N; ; Kelemen LE; Kerin MJ; Kiemeney LA; Kjaer SK; Knight JA; Knol-Bout JP; Konstantopoulou I; Kosma VM; Krakstad C; Kristensen V; Kuchenbaecker KB; Kupryjanczyk J; Laitman Y; Lambrechts D; Lambrechts S; Larson MC; Lasa A; Laurent-Puig P; Lazaro C; Le ND; Le Marchand L; Leminen A; Lester J; Levine DA; Li J; Liang D; Lindblom A; Lindor N; Lissowska J; Long J; Lu KH; Lubinski J; Lundvall L; Lurie G; Mai PL; Mannermaa A; Margolin S; Mariette F; Marme F; Martens JWM; Massuger LFAG; Maugard C; Mazoyer S; McGuffog L; McGuire V; McLean C; McNeish I; Meindl A; Menegaux F; Menéndez P; Menkiszak J; Menon U; Mensenkamp AR; Miller N; Milne RL; Modugno F; Montagna M; Moysich KB; Müller H; Mulligan AM; Muranen TA; Narod SA; Nathanson KL; Ness RB; Neuhausen SL; Nevanlinna H; Neven P; Nielsen FC; Nielsen SF; Nordestgaard BG; Nussbaum RL; Odunsi K; Offit K; Olah E; Olopade OI; Olson JE; Olson SH; Oosterwijk JC; Orlow I; Orr N; Orsulic S; Osorio A; Ottini L; Paul J; Pearce CL; Pedersen IS; Peissel B; Pejovic T; Pelttari LM; Perkins J; Permuth-Wey J; Peterlongo P; Peto J; Phelan CM; Phillips KA; Piedmonte M; Pike MC; Platte R; Plisiecka-Halasa J; Poole EM; Poppe B; Pylkäs K; Radice P; Ramus SJ; Rebbeck TR; Reed MWR; Rennert G; Risch HA; Robson M; Rodriguez GC; Romero A; Rossing MA; Rothstein JH; Rudolph A; Runnebaum I; Salani R; Salvesen HB; Sawyer EJ; Schildkraut JM; Schmidt MK; Schmutzler RK; Schneeweiss A; Schoemaker MJ; Schrauder MG; Schumacher F; Schwaab I; Scuvera G; Sellers TA; Severi G; Seynaeve CM; Shah M; Shrubsole M; Siddiqui N; Sieh W; Simard J; Singer CF; Sinilnikova OM; Smeets D; Sohn C; Soller M; Song H; Soucy P; Southey MC; Stegmaier C; Stoppa-Lyonnet D; Sucheston L; ; Swerdlow A; Tangen IL; Tea MK; Teixeira MR; Terry KL; Terry MB; Thomassen M; Thompson PJ; Tihomirova L; Tischkowitz M; Toland AE; Tollenaar RAEM; Tomlinson I; Torres D; Truong T; Tsimiklis H; Tung N; Tworoger SS; Tyrer JP; Vachon CM; Van 't Veer LJ; van Altena AM; Van Asperen CJ; van den Berg D; van den Ouweland AMW; van Doorn HC; Van Nieuwenhuysen E; van Rensburg EJ; Vergote I; Verhoef S; Vierkant RA; Vijai J; Vitonis AF; von Wachenfeldt A; Walsh C; Wang Q; Wang-Gohrke S; Wappenschmidt B; Weischer M; Weitzel JN; Weltens C; Wentzensen N; Whittemore AS; Wilkens LR; Winqvist R; Wu AH; Wu X; Yang HP; Zaffaroni D; Pilar Zamora M; Zheng W; Ziogas A; Chenevix-Trench G; Pharoah PDP; Rookus MA; Hooning MJ; Goode EL
Gynecol Oncol; 2016 May; 141(2):386-401. PubMed ID: 25940428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
